Norman Fields Gottscho Capital Management LLC Purchases 19,870 Shares of Novo Nordisk A/S (NYSE:NVO)

Norman Fields Gottscho Capital Management LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 45.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,732 shares of the company’s stock after purchasing an additional 19,870 shares during the quarter. Novo Nordisk A/S comprises about 1.8% of Norman Fields Gottscho Capital Management LLC’s portfolio, making the stock its 15th biggest holding. Norman Fields Gottscho Capital Management LLC’s holdings in Novo Nordisk A/S were worth $5,482,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Natixis Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $86,000. Zions Bancorporation N.A. increased its stake in Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Finally, LRI Investments LLC lifted its position in shares of Novo Nordisk A/S by 103.4% during the 3rd quarter. LRI Investments LLC now owns 12,884 shares of the company’s stock valued at $1,534,000 after acquiring an additional 6,550 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 3.1 %

NYSE NVO opened at $84.95 on Tuesday. The company has a market cap of $381.22 billion, a price-to-earnings ratio of 27.49, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s fifty day moving average is $102.51 and its 200 day moving average is $120.68.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.